Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Laboratory predictors of clinical outcomes in patients with atrial fibrillation

https://doi.org/10.20996/1819-6446-2021-04-14

Full Text:

Abstract

Atrial fibrillation (AF) is the most common cardiac arrhythmia in clinical practice that affects intracardiac hemodynamics and is accompanied by increased mortality due to the risk of stroke and systemic thromboembolism. In recent years, numerous studies, evaluating the use of biomarkers in AF patients, have been conducted to expand the possibility of stratification the complications risks.

The aim of the review is to evaluate the possible isolated and combined predictive significance of NT-proBNP, troponin T (TnT) and D-dimer levels in the development and progression of AF and its thromboembolic complications according to published data. Determining the level of NT-proBNP can be used to diagnose cardioembolic stroke in latent forms of AF. Patients with a cardioembolic stroke have been shown to have higher BNP/NT-proBNP levels than patients with an atherothrombotic stroke and venous thromboembolism. Elevated TnT level is independently associated with AF detection as a cause of stroke. The assessment on the CHADS2 scale significantly correlates with the level of troponin I (TnI). However, it is equally important to take into account TnI level even with a low score of CHADS2. Patients with the level of TnI ≥ 0.040 pg/L are considered to be prescribed anticoagulants in the same way as the patients with high CHADS2 score. Similar results were obtained analyzing high-sensitivity cardiac troponin T (hs-cTnT) data. The level of D-dimer 0.315 mg/L was determined to be the optimal limit level for predicting the adverse functional outcome of stroke owing to AF. Patients with a high level of D-dimer have shown a high risk of developing thromboembolic and cardiovascular complications despite their taking anticoagulant drugs. D-dimer levels positively correlate with the CHA2DS2 and CHA2DS2-VASC scales of stroke risk stratification. The analysis of the biomarkers combination has revealed the increase of hs-cTnT and BNP associated with stroke in AF patients (p<0.05). However, ABC scale, including hs-cTnT and NT- pro BNP, hasn't given more accurate result in stroke predicting than CHA2DS2-VASc scale. The integration of biomarkers in predicting the risk of AF occurrence, progression and appearance of thromboembolic complications is a promising direction. An isolated level of biomarkers (hs-cTnT, NT-proBNP, D-dimer) and their combination with clinical risk factors can improve the quality of cardioembolic strokes prognosis.

About the Authors

A. A. Sokolova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Anastasiya A. Sokolova - eLibrary 2153-3542

Moscow



I. V. Goncharova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Irina V. Goncharova

Moscow



A. A. Vedernikov
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Andrey A. Vedernikov

Moscow



N. S. Morozova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Natalia S. Morozova - eLibrary 1124-6231

Moscow



D. A. Napalkov
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Dmitry A. Napalkov - eLibrary 2894-5010

Moscow



References

1. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society. Circulation. 2018;138:421.DOI:10.1161/CIR.0000000000000549.

2. Conen D. Epidemiology of atrial fibrillation. Eur Heart J. 2018;39:1323-4. DOI:10.1093/eurheartj/ehy171.

3. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-962. DOI:10.1016/j.rec.2016.11.033.

4. Haim M, Hoshen M, Reges O, et al. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc. 2015;4:e001486. DOI:10.1161/JAHA.114.001486.

5. Andersson T, Magnuson A, Bryngelsson I, et al. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case-control study. Eur Heart J. 2013;34:1061-7. DOI:10.1093/eurheartj/ehs469

6. Voukalis C, Lip G, Shantsila E. Emerging tools for stroke prevention in atrial fibrillation. EBioMedicine 2016;4:26-39. DOI:10.1016/j.ebiom.2016.01.017.

7. Fuster V, Ryden L, Cannom D, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Circulation. 2006;114:e257-354. DOI:10.1016/j.jacc.2006.07.009.

8. Llombart V, Antolin-Fontes A, Bustamante A, et al. B-Type Natriuretic Peptides Help in Cardioembolic Stroke Diagnosis. Pooled Data Meta-Analysis. Stroke. 2015;46:1187-95. DOI:10.1161/STROKEA-HA.114.008311.

9. Yang HL, Lin YP, Long Y, et al. Predicting cardioembolic stroke with the B-type natriuretic peptide test: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2014;23:1882-9. DOI:10.1016/j.jstroke-cerebrovasdis.2014.02.014.

10. Rodnguez-Yanez M, Sobrino T, Blanco M, et al. High serum levels of pro-brain natriuretic peptide (pro BNP) identify cardioembolic origin in undetermined stroke. Dis Markers. 2009;26:189-95. DOI:10.3233/DMA-2009-0630.

11. Svennberg E, Lindahl B, Berglund L, et al. NT-proBNP is a powerful predictor for incident atrial fibrillation — Validation of a multimarker approach. International Journal of Cardiology. 2016;223:74- 81. DOI:10.1016/j.ijcard.2016.08.001.

12. Yaghi S, Chang A, Ricci B, et al. Early Elevated Troponin Levels After Ischemic Stroke Suggests a Car-dioembolic Source. Stroke. 2018;49:121-6. DOI:10.1161/STROKEAHA.117.019395.

13. Scheitz J, Erdur H, Haeusler K, et al. Insular cortex lesions, cardiac troponin, and detection of previously unknown atrial fibrillation in acute ischemic stroke: insights from the troponin elevation in acute ischemic stroke study. Stroke. 2015;46:1196-201. DOI:10.1161/STROKEAHA.115.008681.

14. Yao T, Tian B, Li G, et al. Elevated plasma D-dimer levels are associated with short-term poor outcome in patients with acute ischemic stroke: a prospective, observational study. BMC Neurol. 2019;19:175. DOI:10.1186/s12883-019-1386-3.

15. Zhang J, Liu L, Tao J, et al. Prognostic role of early D-dimer level in patients with acute ischemic stroke. PLoS ONE. 2019;14(2):e0211458. DOI:10.1371/journal.pone.0211458.

16. Ponikowski P, Voors A, Anker S, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129-200. DOI:10.1093/eurheartj/ehw128.

17. Silvet H, Young-Xu Y, Walleigh D, et al. Brain natriuretic peptide is elevated in outpatients with atrial fibrillation. American Journal of Cardiology. 2003;92(9):1124-7. DOI:10.4065/80.8.1029.

18. Breidthardt T, Noveanu M, Cayir S, et al. The use of B-type natriuretic peptide in the management of patients with atrial fibrillation and dyspnea. International Journal of Cardiology. 2009;136(2):193- 9. DOI:10.1016/j.ijcard.2008.04.045.

19. Goetze J, Friis-Hansen L, Rehfeld J, et al. Atrial secretion of B-type natriuretic peptide. Eur Heart J. 2006;27(14):1648-50. DOI:10.1093/eurheartj/ehl109.

20. Hijazi Z, Oldgren J, Andersson U, et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation. Circulation. 2012;125(13):1605-16. DOI:10.1161/CIRCULATIONAHA.111.038729.

21. Hijazi Z, Wallentin L, Siegbahn A, et al. N-terminal pro-Btype natriuretic peptide for risk assessment in patients with atrial fibrillation. JACC. 2013;;61(22):2274-84. DOI:10.1016/j.jacc.2012.11.082.

22. Dudink EA, Weijs B, Tull S, et al. The Biomarkers NT-proBNP and CA-125 are Elevated in Patients with Idiopathic Atrial Fibrillation. Journal of Atrial Fibrillation. 2018;11(4):2058. DOI:10.4022/jafib.2058.

23. Holl MJ, van den Bos EJ, van Domburg RT, et al. NT-proBNP is associated with mortality and adverse cardiac events in patients with atrial fibrillation presenting to the emergency department. Clin Cardiol. 2018;41:400-5. DOI:10.1002/clc.22883.

24. Sharma S, Jackson PG, Makan J. Cardiac troponins. Journal of Clinical Pathology. 2004;57(10):1025- 6. DOI:10.1136/jcp.2003.015420.

25. Maynard SJ, Menown I, Adgey A. Troponin T or troponin I as cardiac markers in ischaemic heart disease. Heart. 2000;83(4):371-3. DOI:10.1177/0192623316668276.

26. Redfearn DP, Ratib K, Marshall HJ, et al. Supraventricular tachycardia promotes release of troponin I in patients with normal coronary arteries. Int J Cardiol. 2005;102(3):521-2. DOI:10.1016/j.ij-card.2004.05.076.

27. Awke J, Halfor B, Kim E, et al. A review of cardiac and non-cardiac causes of troponin elevation and clinical relevance part I: cardiac causes. Cardiol Curr Res. 2017;(10):3. DOI:10.15406/jccr.2018.11.00360.

28. Roldan V, Marin F, D^az J, et al. High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. J Thromb Haemost. 2012;10(8):1500-7. DOI:10.1111/j.1538-7836.2012.04812.x.

29. Fan Y, Zhao X, Li X, et al. Cardiac troponin and adverse outcomes in atrial fibrillation: A metaanalysis. Clinica Chimica Acta. 2018;477:48-52. DOI:10.1016/j.cca.2017.11.040.

30. Stoyanov KM, Giannitsis E, Biener M, et al. Prognostic value of elevated high-sensitivity cardiac troponin T in patients admitted to an emergency department with atrial fibrillation. Europace. 2018;20(4):582-8. DOI:10.1093/europace/eux063.

31. Sadanaga T, Sadanaga M, Ogawa S. Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. J Am Coll Cardiol. 2010;55:2225-31. DOI:10.1016/j.jacc.2009.12.049.

32. Mahe I, Bergmann JF, Chassany O, et al. A multicentric prospective study in usual care: D-dimer and cardiovascular events in patients with atrial fibrillation. Thromb Res. 2012;129:693-9. DOI:10.1016/j.thromres.2011.08.014.

33. Li-Rui Y, Mei T. The association of high D-dimer level with high risk of ischemic stroke in nonvalvular atrial fibrillation patients. Medicine 2018;97(43):e12622. DOI:10.1097/MD.0000000000012622.

34. Paulin BK, Cedric KK, Tamomh AG, Hui YD. Assessment of cardiac biomarkers (troponin, B-type natriuretic peptide, and D-dimer) in patients with non-valvular atrial fibrillation and stroke. Int J Health Sci (Qassim). 2019;13(6):3-12. PMID: 31745392; PMCID: PMC6852499.

35. Hijazi Z, Lindback J, Alexander JH, et al. The ABC (age, biomarkers, clinical history) stroke risk score:A biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J. 2016;37:1582- 90. DOI:10.1093/eurheartj/ehw054.

36. Yucel O, Yucel H, Zorlu A. D-dimer is a predictor of cardiovascular death, and new-onset atrial fibrillation in patients with systolic heart failure. Int J Cardiol. 2017;247:39. DOI:10.1536/ihj.18-237.

37. Rivera-Caravaca JM, Roldan V, Esteve-Pastor MA, et al. Long-term stroke risk prediction in patients with atrial fibrillation: Comparison of the ABC-stroke and CHA2DS2-VASc scores. J Am Heart Assoc. 2017;6:e006490. DOI:DOI:10.1161/JAHA.117.006490.


For citation:


Sokolova A.A., Goncharova I.V., Vedernikov A.A., Morozova N.S., Napalkov D.A. Laboratory predictors of clinical outcomes in patients with atrial fibrillation. Rational Pharmacotherapy in Cardiology. 2021;17(2):332-340. (In Russ.) https://doi.org/10.20996/1819-6446-2021-04-14

Views: 173


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)